TriangleFOR PATIENTS · SOURCE READING
Treatment of Early Unfavorable Classic Hodgkin Lymphoma
Source: Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 27, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of early unfavorable classic Hodgkin lymphoma in adults may include:
Source links and citations
Combination chemotherapy with or without radiation therapy to the areas of the body with cancer.
Source links and citations
Targeted therapy with a monoclonal antibody (brentuximab vedotin) and combination chemotherapy with or without radiation therapy.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice